Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27332852 | 0.97 | — | — | |
| SCHEMBL2478796 | 0.83 | CA12 (0.35) | CYP1A2MAPK1CA12CA1CA2 | |
| SCHEMBL20811 | 0.79 | — | — | |
| SCHEMBL21026948 | 0.77 | — | — | |
| SCHEMBL21937581 | 0.77 | — | — | |
| SCHEMBL18502210 | 0.77 | — | — | |
| SCHEMBL15179240 | 0.77 | ALDH1A1 (0.36) | — | |
| SCHEMBL20663578 | 0.77 | — | — | |
| SCHEMBL7856150 | 0.77 | FDPS (0.36) | CA1FDPS | |
| SCHEMBL20243279 | 0.77 | TSHR (0.40) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163022-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4452963-A1 | PARP1 INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118696036-A | PARP1 inhibitors | 突触活化疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110130538-A1 | PHOTOLYTIC ACID-GENERATING POLYMERS AND MONOMERS FOR THEIR CONSTRUCTION | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2011-06-02 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-7169814-B2 | Guanidinium transport reagents and conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20030143607-A1 | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof | YANG GUOHAN (US) | 2003-07-31 | — | — | US | disclosed |
| US-6504019-B2 | Used in place of conventionally labeled oligonucleotides for a variety of hybridization reactions | BAYER CORPORATION | 2003-01-07 | — | — | US | disclosed |
| US-20020015953-A1 | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof | BAYER CORPORATION | 2002-02-07 | — | — | US | disclosed |
| EP-1136569-A2 | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof | Bayer Corporation (US) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | CYP1A2 1678/4885MAPK1 3196/4885CA12 4755/4885 |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | CYP1A2 1779/4885MAPK1 1559/4885CA12 4580/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | CYP1A2 3539/4885MAPK1 2873/4885CA12 3434/4885 |
| US-20250163022-A1 | PARP1 INHIBITORS | PARP1, PARP11, PARP12 | CYP1A2 4164/4885MAPK1 1787/4885CA12 4719/4885 |
| US-20110130538-A1 | PHOTOLYTIC ACID-GENERATING POLYMERS AND MONOMERS FOR THEIR CONSTRUCTION | PPOX, ALAD, PGAM1 | CYP1A2 1938/4885MAPK1 1926/4885CA12 2616/4885 |
| US-20020015953-A1 | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof | DNTT, NSUN3, NCL | CYP1A2 4874/4885MAPK1 4303/4885CA12 2952/4885 |
| US-20030143607-A1 | Nucleic acid probes having highly hydrophilic non-nucleosidic tags with multiple labels, and uses thereof | DNTT, NSUN3, NCL | CYP1A2 4874/4885MAPK1 4303/4885CA12 2952/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CYP1A2 50/4885MAPK1 4173/4885CA12 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.